Bruno Royer

Bruno Royer

Auto-generated profile, based on publicly available information

Bruno Royer

Department of Immuno‐Hematology, APHP, Saint Louis Hospital University of Paris Paris France

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2014 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
JPJulien Paccou
Julien Paccou
LML. Merlusca
L. Merlusca
IHI. Henry-Desailly
I. Henry-Desailly
APA. Parcelier
A. Parcelier
BGB. Gruson
B. Gruson
GDG. Damaj
G. Damaj
Bone mineral density (BMD) loss is poorly defined in lymphoma patients. The aim of this study was to measure the extent of BMD loss in newly diagnosed lymphoma patients receiving chemotherapy. This was a prospective, single-center study conducted in patients aged ≥18 years with previously confirmed lymphoma treated by chemotherapy. Patients with low baseline BMD defined as Z/T-score less than or equal to −2.5 and/or history of osteoporotic fractures were excluded. BMD was measured at baseline before initiating chemotherapy and 1 year later. Predictive factors of BMD loss were investigated. Forty-one lymphoma patients (31 males and 10 females) receiving chemotherapy were enrolled. The median age at diagnosis was 59 (range: 19–86) years. Histological subtypes were predominantly diffuse large B-cell lymphoma (58%), mostly stage III–IV (54%). All patients received chemotherapy and 22% of patients received second-line treatment due to relapse or progressive disease. Thirty-two patients were evaluable at 1 year. The mean BMD changes were: −2.7% ± 3.9% for lumbar spine (P < 0.001), −2.2% ± 7.6% for femoral neck (P < 0.01) and −2.6% ± 4.5% for total hip (P < 0.0001). In multivariate analysis, predictive factors of BMD loss at baseline were (i) at lumbar spine: female gender (P = 0.01), higher lactate dehydrogenase level (P = 0.04) and lower creatinine clearance (P = 0.01); (ii) at total hip: lower albumin (P = 0.01), higher corrected serum calcium (P < 0.01), lower alkaline phosphatase (AP) (P < 0.01) and autologous stem cell transplant (P = 0.03); and (iii) at femoral neck: higher corrected serum calcium (P = 0.02) and lower bone AP (P = 0.01). Adult patients with known lymphoma receiving chemotherapy experienced significant BMD loss at 1 year.

24 March 2014 in International Journal of Laboratory Hematology
Verified
Journal Article
Closed access
PDF file
VPV. Petitprez
V. Petitprez
BRB. Royer
B. Royer
JDJ. Desoutter
J. Desoutter
EGEric Guiheneuf
Eric Guiheneuf
ARA. Rigolle
A. Rigolle
NGNicolas Guillaume
Nicolas Guillaume

9 March 2021 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
ACAlexis Claudel
Alexis Claudel
ATAlexis Talbot
Alexis Talbot
SHStéphanie Harel
Stéphanie Harel
BRBruno Royer
Bruno Royer
LNLombion Naelle
Lombion Naelle
BABertrand Arnulf
Bertrand Arnulf
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.

10 February 2022 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
EPElodie Portier
Elodie Portier
ATAlexis Talbot
Alexis Talbot
YNYann Nguyen
Yann Nguyen
BRBruno Royer
Bruno Royer
MPMagali Pettazzoni
Magali Pettazzoni
NBNadia Belmatoug
Nadia Belmatoug
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.

5 November 2021 in Blood
Verified
Journal Article
Open access
Aurore PerrotAurore Perrot
Aurore Perrot
CHCyrille Hulin
Cyrille Hulin
MMMargaret Macro
Margaret Macro
LFLaurent Frenzel
Laurent Frenzel
CACarla Araujo
Carla Araujo
ODOlivier Decaux
Olivier Decaux
Background EMMY is a large-scale epidemiological study to assess the epidemiology and real-life management of multiple myeloma (MM). Proteasome inhibitors (PI), immunomodulators (IMID) and anti-CD38, provide broad therapeutic solutions for the management of first-line Multiple Myeloma (MM). At more advanced stages, the therapeutic possibilities in patients already exposed to these 3 therapeutic classes are limited. The EMMY study allows to describe the characteristics and the real-life efficacy of treatments in tri-exposed patients. Methods EMMY is a descriptive, multicenter, national, non-interventional study conducted in 72 IFM (Intergroupe Francophone du Myélome, sponsor) centers in France. Any patient initiating treatment for MM over a 3-month observation period, from October to December, is included, since 2017. It is a dynamic cohort with the inclusion of 1000 additional patients each year (2765 patients included at the end of 2019). Data are updated annually from hospital records up to 2020. Patients with tri-exposure to the 3 classes IMID, IP and anti CD38 were identified, and the index date was defined as the initiation of the next line. The median time to next treatment (mTTNT), median progression-free survival (mPFS), and median overall survival (mOS) were estimated for these patients. Results are focused in patients refractory to the previous line (PL-Ref). Results After 3 years of data collection in EMMY, 491 patients (17.8%) were identified as tri-exposed in the cohort. The median age was 69.9 years [62.2-75.8] with 158 patients (32.2%) < 65 years and 63 (12.8%) ≥ 80 years. When available, patients had ECOG 0 or 1 for 59.3% (n=211), high cytogenetic risk for 29.5% (RD) (n=65), an ISS of 1/2/3 for 25.3, 28.5 and 46.2% and at least one comorbidity for 32% (n=157). The patients were tri-exposed at the end of L2, L3, L4, L5 and L6+ for respectively 2%, 16.9%, 26.9%, 26.3% and 27% of them with a median time from diagnosis to the index date of 54.9 months (mo) [32.9 -89.7]. The proportion of patients early tri-exposed as of L3 or L4 increased over the years with respectively 9.8% (L3) and 15.7% (L4) in 2017 (n=51), 11% and 18.9% in 2018 (n=127), 17.1% and 26.8% in 2019 (n=164) and 24.5% and 37.4% in 2020 (n=147). Time from diagnosis to the index line decreased from 64.6 mo (2017) and 62.8 mo (2018) to 54.5 mo (2019) and 49.5 mo (2020). Half patients (52.5%) had previously received ASCT. At the index date, patients had previously been treated with bortezomib (98%), carfilzomib (21.2%), ixazomib (10.4%), lenalidomide (90.4%), thalidomide (35.8%), pomalidomide (61,9%), daratumumab (96.5%) and isatuximab (3.5%). In overall, 86% were refractory to anti-CD38, 51% refractory to 3 classes, and 31% to 2 classes. Of them, 89.2% (438) were refractory to the line prior to the index line (PL-Ref). The mPFS was 5,1 mo 95%CI [4.4 - 6.3] and the mTTNT 6.9 mo 95%CI [6.1 -8.2] for the whole cohort (n=481). In the 438 PL-Ref patients, mPFS was 4.8 mo 95%CI [4.1-6] and mTTNT was 6.6 mo 95%CI [5.5; 7.8] (Figure 1). The mOS was 17.7mo 95%CI [14.2 - 20.2] for the whole cohort with mOS of 16.6 mo 95%CI [13.1 - 19.8] in PL-Ref patients. Conclusion Advances in the management of myeloma are leading to the increasingly early use of combination treatments with IMID, PI and anti-CD38 antibodies in the treatment of multiple myeloma. As a result, patients are increasingly early exposed to these 3 major classes. The EMMY cohort confirms that patients are triple exposed to PIs, IMID, and anti CD38 at an increasingly early stage in the management of MM. Most of them were refractory to the last line and to anti-CD38 antibodies. The majority remains healthy with ECOG less than 2 and few comorbidities. Median PFS and TTNTs are approximately six months, lower than those observed with modern anti-BCMA immunotherapies. These results underline the importance of developing new therapeutic strategies in triple-exposed patients such as novel immunotherapy including bi-specific antibody/CART cells.